| Pronounce: | dak" oh mi' ti nib |
| Tradename: | Vizimpro |
| Dailymedid: | Dacomitinib |
| Routes Of Administration: | By mouth |
| Atc Prefix: | L01 |
| Atc Suffix: | EB07 |
| Legal Ca: | Rx-only |
| Legal Ca Comment: | [1] [2] |
| Legal Us: | Rx-only |
| Legal Eu: | Rx-only |
| Legal Status: | Rx-only |
| Bioavailability: | 80% |
| Protein Bound: | 98% |
| Metabolism: | CYP2D6, CYP3A4 |
| Metabolites: | O-desmethyl-dacomitinib |
| Elimination Half-Life: | 70 hrs |
| Excretion: | 79% faeces, 3% urine |
| Index2 Label: | as salt |
| Cas Number: | 1110813-31-4 |
| Pubchem: | 11511120 |
| Drugbank: | DB11963 |
| Chemspiderid: | 9685914 |
| Unii: | 2XJX250C20 |
| Kegg: | D09883 |
| Kegg2: | D10514 |
| Chebi: | 132268 |
| Chembl: | 2105719 |
| Iuphar Ligand: | 7422 |
| Pdb Ligand: | 1C9 |
| Synonyms: | PF-00299804 |
| Iupac Name: | (2E)-N--4-(1-piperidinyl)-2-butenamide |
| C: | 24 |
| H: | 25 |
| Cl: | 1 |
| F: | 1 |
| N: | 5 |
| O: | 2 |
| Smiles: | COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)/C=C/CN4CCCCC4 |
| Stdinchi: | 1S/C24H25ClFN5O2/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29)/b6-5+ |
| Stdinchikey: | LVXJQMNHJWSHET-AATRIKPKSA-N |
Dacomitinib, sold under the brand name Vizimpro, is a medication for the treatment of non-small-cell lung carcinoma (NSCLC). It is a selective and irreversible inhibitor of EGFR.[3]
Dacomitinib has advanced to several Phase III clinical trials. The January 2014 results of the first trials were disappointing, with a failure to meet the study goals,[4] [5] [6] but additional Phase III trials continued.[4] In 2017, results of a trial comparing dacomitinib to gefitinib for NSCLC (driven by mutated EGFR) were announced.[7]
Dacomitinib was approved for medical use in the United States in September 2018,[8] in Japan in 2019, and in the European Union in 2019,[9] for the treatment of non-small cell lung cancer with epidermal growth factor receptor (EGFR) gene mutation.